Company: INSP
Filing Date: 2025-03-18
Form Type: DEF 14A
Source: 0001140361-25-009249
Chunk: 22

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-03-18
Form: DEF 14A
Chunk 22
---
 we will pay the compensation of any such firm or advisor engaged. For fiscal 2024, our Nominating and Corporate Governance Committee consisted of Dr. Curet, Mr. Ellis, Dr. Griffin (until Dr. Griffin did not stand for re-election at the 2024 annual meeting of stockholders), Ms. Nelson (until Ms. Nelson did not stand for re-election at the 2024 annual meeting of stockholders), and Mr. Mead (effective following the 2024 annual meeting of stockholders), with Mr. Ellis serving as chair. Our Nominating and Corporate Governance Committee currently consists of Ms. Broader (who joined the committee in February 2025), Dr. Curet, Mr. Ellis and Ms. Garinois-Melenikiotou (who joined the committee in February 2025), with Mr. Ellis serving as chair. Mr. Mead transitioned off the committee in February 2025 in connection with assuming the role of Chair of the Quality, Product Supply, and Technology Committee. Our Board has determined that each of Ms. Broader, Dr. Curet, Mr. Ellis, and Ms. Garinois-Melenikiotou qualifies as “independent” under applicable NYSE rules for purposes of serving on the Nominating and Corporate Governance Committee. Quality, Product Supply, and Technology Committee Our Quality, Product Supply, and Technology Committee oversees and assists our Board in carrying out the Board’s oversight responsibilities over the quality, safety, and supply of the Company’s products, the Company’s compliance with legal and regulatory requirements and the Company’s Code of Conduct, and the Company’s research, innovation, and technology initiatives and programs. The committee is responsible for, among other things:

| • | overseeing risk management of product quality, safety, and supply matters, including the Company’s strategy and systems in place to monitor the quality and safety of the Company’s products, the Company’s quality management systems, significant product complaints and recalls, and FDA regulatory inspections and warning letters; |

| • | monitoring the Company’s compliance and ethics program, including compliance with healthcare legal and regulatory requirements, regulatory submissions and registrations, and compliance with the Code of Conduct; |

| • | overseeing the Company’s research and development activities, innovation and technology strategy, product and therapy development pipeline, clinical trials, and intellectual property portfolio; and |

| • | reviewing the Company’s strategy and opportunities for new ventures, investments, acquisitions, and other strategic transactions. |

Our Quality, Product Supply, and Technology Committee currently